<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03488914</url>
  </required_header>
  <id_info>
    <org_study_id>R01DA041262</org_study_id>
    <nct_id>NCT03488914</nct_id>
  </id_info>
  <brief_title>Examining Community-based Effectiveness of a Substance Use and HIV Risk Reduction Intervention for Young Men of Color</brief_title>
  <acronym>YMHP-CBO</acronym>
  <official_title>Examining Community-based Effectiveness of a Substance Use and HIV Risk Reduction Intervention for Young Men of Color</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunter College of City University of New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Hunter College of City University of New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will conduct an effectiveness trial of the 4-session evidence-based YMHP&#xD;
      intervention for YMSM of color ages 15-29 at two CBOs in New York City, compared to usual&#xD;
      care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will conduct a comparative effectiveness trial (CET) with two intensities of treatment to&#xD;
      be offered following field-based HIV counseling and testing (C&amp;T) - the YMHP intervention and&#xD;
      an enhanced &quot;treatment as usual&quot; (eTAU) condition involving HIV prevention services provided&#xD;
      at two community based organizations (CBOs) to test their relative effectiveness in reducing&#xD;
      substance use and sexual risk behavior among HIV-negative MYMSM. In collaboration with two&#xD;
      CBOs, our goals are to better understand substance use and sexual health-related outcomes&#xD;
      among HIV-negative MYMSM who are unlikely to be treatment seeking and to implement the YMHP&#xD;
      intervention in a way that will maximize portability and scalability. Working together with&#xD;
      our collaborators will help to address practical problems at the frontline of service&#xD;
      provision to pave the way for a comprehensive program to reduce substance use and HIV&#xD;
      infection among MYMSM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 15, 2016</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Randomization to YMHP or enhanced Treatment as Usual (eTAU)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Days of Drug Use</measure>
    <time_frame>Past 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Condomless Anal Sex Acts</measure>
    <time_frame>Past 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>STI</measure>
    <time_frame>Past 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PrEP Uptake</measure>
    <time_frame>Past 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Substance Use</condition>
  <condition>Sexual Risk</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced Treatment as Usual</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>YMHP Intervention</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Enhanced Treatment as Usual</intervention_name>
    <arm_group_label>Enhanced Treatment as Usual</arm_group_label>
    <other_name>eTau</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-negative test result from the past 90 days&#xD;
&#xD;
          -  15-29 years of age&#xD;
&#xD;
          -  Born biologically male or currently identifying as male&#xD;
&#xD;
          -  Sex with men in the past 90 days&#xD;
&#xD;
          -  ≥ 5 days of illicit drug use in the past 90 days&#xD;
&#xD;
          -  ≥ 1 episode of CAS in the past 90 days, or a positive STI test result in the past 90&#xD;
             days.&#xD;
&#xD;
          -  Living in the New York City area&#xD;
&#xD;
          -  Able to communicate in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious cognitive or psychiatric impairments&#xD;
&#xD;
          -  ≥5 days of IDU drug use in the past 90 days&#xD;
&#xD;
          -  Currently taking Truvada as Pre-Exposure Prophylaxis (PrEP)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tyrel J Starks, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunter College, CUNY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BOOM!Health</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridging Access to Care</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunter College of City University of New York</investigator_affiliation>
    <investigator_full_name>Tyrel Starks</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing with scientific and health service community: We will have compiled structured de-identified datasets and can make them available for additional/secondary data analyses. It is our explicit intention that these data be readily accessible. We will collaborate with and make our data available to other researchers for additional/secondary analyses. Formal data sharing agreements will be developed to guide and encourage further data mining of the proposed datasets for various purposes.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>As per NIH policy</ipd_time_frame>
    <ipd_access_criteria>The dissemination of any and all data collected under the NIH data sharing agreement will be released: a) In a timely manner following the time line of the project provide; and b) To the broader community, in accordance with NIH guidelines. Active dissemination to collaborators, community groups and through peer-reviewed articles will facilitate access to the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

